Posted by Michael Wonder on 26 Jul 2023
Selpercatinib for untreated RET fusion positive advanced non-small-cell lung cancer
26 July 2023 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for adults with advanced, RET fusion positive non-small-cell lung cancer.
Selpercatinib is recommended with managed access as an option for the first-line treatment of adults with advanced RET fusion positive non-small-cell lung cancer.
